Clinical Trial

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Name: Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma — clinical trial record (NCT07388758)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to explore the efficacy and safety of scipibaimab combined with tislelizumab in patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after first-line therapy.

Trial Details

NCT Number	NCT07388758
Lead Sponsor	Sun Yat-sen University Collaborators: Sichuan Cancer Hospital and Research Institute, Cancer Hospital of Guangxi Medical University
Conditions	Nasopharyngeal Carcinoma (NPC)
Enrollment	37 participants
Start Date	2026-02
Primary Completion	2028-02 (estimated)
Study Completion	2029-02 (estimated)
Updated on ClinicalTrials.gov	2026-02-05